Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(12): 1351-60, 2014 Nov.
Article
in En
| MEDLINE
| ID: mdl-25273343
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Taxoids
/
Deoxycytidine
/
Antibodies, Monoclonal, Humanized
/
Fluorouracil
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2014
Type:
Article